skip to content


Issue No. 7 | February 22, 2013

News and Features

HHS Perinatal Guideline Panel Accepting Nominations for New Members

The Department of Health and Human Services (HHS) Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission in the United States (or the Panel) is accepting nominations for a new community member and new scientific/clinical members.

Panel members critically evaluate the latest HIV treatment-related information and prepare guideline revisions. The Panel is seeking new members available to serve a 3-year term beginning April or May 2013, with potential for reappointment for an additional term.

Nominations must be received by March 22, 2013.

Complete details on new member qualifications and instructions regarding nominations are available:

Voluntary Recall Announced for One Lot of Cidofovir Injection (Vistide) Solution

“Gilead Sciences, Inc. is voluntarily recalling lot B120217A of Vistide® (cidofovir injection) to the user level due to the presence of  particulate matter found in some vials of this lot. Gilead is not currently aware of any complaint attributable to the particles. …

“Vistide is indicated for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). …

“Gilead has notified its distributors and customers by e-mail and recall letter and is arranging for return of all recalled product. Before injecting Vistide, healthcare providers should inspect the product and any product with lot number B120217A should not be injected.

“Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to using Vistide.”

More information is available:

Institute of Medicine Releases Report: Evaluation of PEPFAR

On February 20, the Institute of Medicine (IOM) released a report evaluating the United States President's Emergency Plan for AIDS Relief (PEPFAR).

The report was authored by the Committee for the Outcome and Impact Evaluation of Global HIV/AIDS Programs Implemented Under the Lantos/Hyde Act of 2008.

More information is available: